Astute Medical

Astute is working with Fosun on Chinese trials for the test that it will use to gather data for a submission to the Chinese Food and Drug Administration.

The company has no plans to position NephroCheck for long-term prognosis but said the findings bolster data supporting use of the test in the acute setting.

From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.

NEW YORK (GenomeWeb) – With the recent clearance by the US Food and Drug Administration of its NephroCheck test for acute kidney injury, Astute Medical has achieved a milestone under the terms of its loan agreement with CRG which releases from CRG up to $30 million to support commercialization of

NEW YORK (GenomeWeb) – Astute Medical said this week that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.

NEW YORK (GenomeWeb) – Astute Medical said today that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.

NEW YORK (GenomeWeb) – Astute Medical said this week that it has entered a strategic collaboration with Ortho-Clinical Diagnostics to expand sales of its NephroCheck test for acute kidney injury.

A paper published last week in PLOS One indicates that Astute Medical's NephroCheck test can help predict development of acute kidney failure in patients after undergoing cardiac surge

Researchers have completed a prospective, multi-center clinical trial validating the performance of Astute Medical's NephroCheck protein biomarker test for acute kidney disease.

Combining metabolomics and proteomics, a consortium of academic and industry researchers has identified a signature that appears useful for predicting death in sepsis patients.

Pages

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.